Immuno-oncology company Affimed to be delisted from Nasdaq after insolvency filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Affimed N.V. Delisting Notice: Affimed N.V. received a notice from Nasdaq regarding the suspension of its shares effective May 20, 2025, following its filing for insolvency in Germany on May 13, 2025.
Stock Price Decline: The company's stock price fell by 10% to $0.12 during pre-market trading after the announcement of its insolvency proceedings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
